<DOC>
	<DOCNO>NCT02627287</DOCNO>
	<brief_summary>This trial conduct Europe . The aim trial compare Injections Medical Device DV3316 Pen-injector versus FlexPen® .</brief_summary>
	<brief_title>A Comparative Trial Focusing Injections With Medical Device DV3316 Pen-injector Versus FlexPen®</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<criteria>Male female age 1874 year ( include ) time sign informed consent T1DM ( Type 1 Diabetes Mellitus ) T2DM ( Type 2 Diabetes Mellitus ) ( diagnose clinically ) least 12 month prior screen Daily selfinjection ( ) antidiabetic drug ( insulin GlucagonLike Peptide1 ( GLP 1 ) analogue ) peninjector vial/syringe least 12 month Caucasians Body Mass Index ( BMI ) least 18.5 kg/m^2 Known suspected hypersensitivity test placebo solution incl . mcresol phenol related product ( placebo ) Female pregnant , , breastfeed intend become pregnant childbearing potential use adequate contraceptive method ( adequate contraceptive measure require local law practice ) Known urticaria factitive abnormal reaction mechanical trauma Haemophilia diseases affect blood coagulation Anticoagulant inhibitor platelet aggregation treatment day visit Intake painrelieving analgesic drug day site visit Skin diseases infection skin injection site area ( abdomen thighs ) Lipodystrophia injection site area ( abdomen thigh )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>